When it comes to detecting rare cancer-causing mutations, both sensitivity and specificity matter. In the past few years, digital PCR (dPCR) has captured the attention of researchers and clinicians ...

Digital PCR (dPCR) has emerged as a powerful tool in genetic analysis, offering improved precision, sensitivity, and accuracy compared to traditional methods. In this webinar, we will provide an ...

Digital PCR (dPCR) is a powerful technology for detecting and quantifying nucleic acids. In dPCR, nucleic acids within a sample are randomly distributed into numerous small-volume micro-reactions and ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and NuProbe USA, a genomics and molecular diagnostics company, recently ...

BOSTON--(BUSINESS WIRE)--Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla ...

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...

Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise ...

Various approaches have been developed to identify and quantitate copy-number variation. A new, high-resolution approach that already shows promise is digital PCR. As illustrated by many research ...

FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 ...

VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR ...